RBC Capital analyst Daniel Busby maintained a Buy rating on Aquestive Therapeutics (AQST) on May 6 and set a price target of $7.00.
The post RBC Capital Thinks Aquestive Therapeutics Stock is Going to Recover appeared first on Smarter Analyst.
RBC Capital analyst Daniel Busby maintained a Buy rating...

https://www.smarteranalyst.com/new-blurbs/rbc-capital-thinks-aquestive-therapeutics-stock-is-going-to-recover/

#SmarterAnalyst